REG - Provexis PLC - Director/PDMR Shareholding
RNS Number : 1765MProvexis PLC12 September 201912 September 2019
Provexis plc
("Provexis" or the "Company")
Director / PDMR notification
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.
Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Ian Ford (Director and PDMR) - shares acquired on behalf of Mr Ford's children (under the age of 18) who are persons closely associated with Mr Ford
2
Reason for the notification
a)
Position/status
See 1a) above
b)
Initial notification
/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
PROVEXIS PLC
b)
LEI
21380042E3Y3N9VZ6N48
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1p each
ISIN: GB00B0923P27
b)
Nature of the transaction
Purchase of ordinary shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
0.33 pence
and
0.345 pence
2,500,000
2,500,000
d)
Aggregated information
- Aggregated volume
- Price
5,000,000 shares
Average price of 0.338 pence per share
e)
Date of the transaction
12 September 2019
f)
Place of the transaction
London Stock Exchange, AIM Market
For further information please contact:
Provexis plc
Dawson Buck, Chairman
Ian Ford, CEO & CFO
Tel: 07490 391888
enquiries@provexis.com
Allenby Capital Limited
Nick Naylor / Liz Kirchner
Tel: 020 3328 5656
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Provexis was founded in 1999 and is headquartered in Reading, Berkshire.
Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com and www.fruitflowplus.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHGGUQGBUPBGCP
Recent news on Provexis
See all newsREG - Provexis PLC - Grant of Options and Warrants
AnnouncementREG - Provexis PLC - Total Voting Rights
AnnouncementREG - Provexis PLC - Half-year Report
AnnouncementREG - AIM - AIM Notice - 24/12/2024
AnnouncementREG - Provexis PLC - Purchase of Fruitflow® II SD & royalty payment
Announcement